Wuxi to Help Develop, Manufacture ADC Candidate in China
Ambrx and Zhejiang Medicine have selected Wuxi to accelerate the development of a potential ADC (antibody drug conjugate) targeting Her2-positive breast cancer.
Archives for June 18, 2013
It Had To Be Yew? Not So Says Phyton With New Docetaxel CEP
Phyton Biotech has received European approval for a version the cancer drug API docetaxel whose production does not rely on the scarce yew tree extract used in traditional manufacturing methods.